Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
AstraZeneca's oral relaxin drug AZD5462 hits its HFpEF endpoint but narrowly misses in HFrEF in the Phase 2b LUMINARA heart ...
CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to ...
Lilly's Mounjaro wins a CV nod, Teva buys BioXcel's assets, AusperBio raises $120M and Samsung Biologics preps a $2.2B raise.
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in ...
Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer.
AstraZeneca and Ionis's Wainua misses in Phase 3 heart trial CARDIO-TTRansform, likely due to overlap with Pfizer's Vyndamax; ...
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results